ICER Report on Eliquis, Xarelto May Aid Drug Price Negotiations
The Institute for Clinical and Economic Review (ICER) published a report on Oct. 2 evaluating the blood thinners Eliquis (apixaban) and Xarelto (rivaroxaban), two of the 10 drugs that will be subject to Medicare price negotiations starting in 2026.
Based on ICER’s modeling and review of the available evidence, the organization determined that Eliquis and Xarelto could have substantial price premiums over warfarin. However, when compared with dabigatran, ICER noted that Eliquis could have a smaller price premium and Xarelto could have no price premium. Warfarin and dabigatran are both generic drugs that are competitors to Eliquis and Xarelto.
© 2025 MMIT
Related Posts

September
1
Medicare Drug Price Negotiation: ‘Spillover Effect’ on Private Market Remains Fuzzy
READ MORE
September
1
Majority of Drugs Selected for Price Negotiation Are on ‘Preferred’ Tiers in Medicare
READ MORE
August
24